Zalyalova Z A, Khasanova D M
Kazan State Medical University, Kazan, Russia.
Rebublican Center for Movement Disorders, Kazan, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(9):152-156. doi: 10.17116/jnevro2021121091152.
The article provides an overview of the data on the impact of Parkinson's disease on the risk of infection and the course of COVID-19, and also assesses the possible pathogenetic relationship between the SARS-CoV-2 virus, COVID-19 and PD. By penetrating the central nervous system, SARS-CoV-2 can cause not only neurological symptoms, but also exacerbate the course of an existing neurological disease. The impact of Parkinson's disease on the risk of infection and the course of COVID-19 is controversial. However, a number of authors support the opinion that PD is an anti-risk factor for the development of COVID-19, which is associated both with the pathogenesis of the disease and with the used antiparkinsonian drugs, in particular amantadines. There are no clear data indicating higher risk of infection and higher severity of COVID-19 in patients with PD. On the contrary, experimental and clinical data suggest a possible modifying role of α-synuclein and antiparkinsonian drugs.
本文概述了帕金森病对感染风险和新冠病毒病病程影响的数据，还评估了严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒、新冠病毒病和帕金森病之间可能的发病机制关系。SARS-CoV-2通过侵入中枢神经系统，不仅可引起神经症状，还会加重现有神经疾病的病程。帕金森病对感染风险和新冠病毒病病程的影响存在争议。然而，一些作者支持帕金森病是新冠病毒病发病的抗风险因素这一观点，这与疾病的发病机制以及所用的抗帕金森病药物（特别是金刚烷胺）都有关。目前尚无明确数据表明帕金森病患者有更高的感染风险和更严重的新冠病毒病。相反，实验和临床数据提示α-突触核蛋白和抗帕金森病药物可能具有调节作用。
